Alice Blackman

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Tanguy Y. Seiwert, Jérôme Fayette, Didier Cupissol et al. · Annals of Oncology · 2014 · 182 citations · Full text

Medicine, Oncology, Pharmacology +17

BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Tanguy Y. Seiwert, Paul M. Clément, Didier Cupissol et al. · Journal of Clinical Oncology · 2010 · 39 citations

Medicine, Oncology, Pharmacology +9

A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover.

Didier Cupissol, Tanguy Y. Seiwert, Jérôme Fayette et al. · Journal of Clinical Oncology · 2013 · 22 citations

Medicine, Oncology, Pharmacology +16

A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Tanguy Y. Seiwert, Jérôme Fayette, Didier Cupissol et al. · Annals of Oncology · 2012 · 17 citations

Medicine, Oncology, Cancer Pharmacology +13